Clinical Trials Logo

Clinical Trial Summary

GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor. The study aim to Evaluate the Safety and efficiency of Using the neoadjuvant therapy with Carilizumab and Apatinib in patients with Recurrent High-Grade Glioma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04588987
Study type Interventional
Source Sun Yat-sen University
Contact Chen Zhong ping, PHD
Phone 020-8734009
Email chenzhp@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date October 2020
Completion date May 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Recruiting NCT06138496 - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Phase 2
Not yet recruiting NCT05983094 - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer Phase 2
Terminated NCT04440982 - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Phase 2
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05993858 - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC Phase 2
Active, not recruiting NCT04666090 - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Recruiting NCT04062058 - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06124378 - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Phase 2
Not yet recruiting NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Not yet recruiting NCT06404736 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Phase 2
Not yet recruiting NCT06404463 - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Phase 2
Recruiting NCT05371197 - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Phase 2
Recruiting NCT06212440 - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy N/A
Completed NCT03178032 - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT02769104 - Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer Phase 3